Argenx is ending a large Phase 3 study of its drug efgartigimod in Sjögren's disease after independent monitors concluded the trial cannot meet its main goal. The company announced the decision Oct. 8.
An independent data monitoring committee reviewed an interim analysis of the UNITY trial and recommended stopping it for futility, according to an argenx statement. The company said safety was consistent with the drug's established profile and that no new safety signals were identified.
